All In Biotech

Drug Trial Radar · NCT07348302

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Prospective, Randomised, DBPC, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma, Allergic to Dpt and/or Df

Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 736 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

736

Planned (sponsor's estimate)

Start

Apr 2, 2025

Primary completion

Apr 27, 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Inmunotek S.L.Industry
Sponsor type
Industry
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09. The main questions it aims to answer are: Does MM09 reduce the symptoms and the need of rescue medication? What medical problems do participants have when inhaling MM09? Researchers will compare MM09 to a placebo (a look-alike substance that contains no drug) to see if MM09 works to treat rhinitis/rhinoconjunctivitis.

Conditions

  • Rhinitis
  • Rhinoconjunctivitis

Interventions

  • Allergen Immunotherapy ExtractBiological

    Sublingual spray, solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RCSMS : Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication ScoreTime frame: last 4 weeks of IMP treatment

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • Fundación CIDEA

    Buenos Aires, Argentina · Active not recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • Centro de Educación Medica de Investigaciones Clinicas "Norberto Quirno" (CEMIC)

    Buenos Aires, Argentina · Recruiting

  • Centro Médico Vitae

    Nueve de Julio, Buenos Aires, Argentina · Recruiting

  • Centro de Investigaciones Clínicas - Instituto de Especialidades de la Salud Rosario

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Centro Respiratorio Infantil

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Union Hospital Tongji Medical College of HUST

    Huangzhou, China · Recruiting

  • Beijing Tongren Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Third Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Zhongshan, Guangzhou, China · Not yet recruiting

  • The Third Xiangya Hospital of Central South University

    Xiangya, Hunan, China · Recruiting

  • Changzhou Third People's Hospital

    Changzhou, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Eye & ENT Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tongji Hospital Tongji Medical College of HUST

    Tongji, Wuhan, China · Recruiting

  • Unidade de Local de Saúde de Santo António, E.P.E.

    Porto, Portugal · Not yet recruiting

  • ULS Lezíria- Hospital Distrital de Santarém

    Santarém, Portugal · Not yet recruiting

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain · Active not recruiting

  • Hospital IMED Benidorm

    Benidorm, Alicante, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.